Who
George Golumbeski
Director
Company insider
Files Form 4 as: Director, Acumen Pharmaceuticals; Director, Shattuck Labs; Director, Mural Oncology; Director, Sage Therapeutics; Director, Corbus Pharmaceuticals Holdings; Director, Enanta Pharmaceuticals.
In numbers
- Trades disclosed
- 57
- Buys
- 4
- Sells
- 3
- Bought
- $451K
- Sold
- $2.2M
- Companies
- 6
- Companies where not an officer
- 6
- First trade
- 7 Feb 2014
- Last trade
- 3 Jun 2026
- Last filed
- 5 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Jun 2026filed 5 Jun 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —35,500 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | ABOS Acumen Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —53,250 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | ABOS Acumen Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —53,250 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —35,500 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | STTK Shattuck Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —81,000 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | STTK Shattuck Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —81,000 at $0.00 | filing |
| 5 Dec 2025filed 5 Dec 2025 | Mural Oncologyoption or derivative | SEC FORM 4 Code D | —8,637 | filing |
| 5 Dec 2025filed 5 Dec 2025 | Mural Oncologyoption or derivative | SEC FORM 4 Code D | —15,334 | filing |
| 6 Nov 2025filed 10 Nov 2025 | ABOS Acumen Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 31 Jul 2025filed 31 Jul 2025 | Sage Therapeuticsoption or derivative | SEC FORM 4 Code D | —13,593 | filing |
| 31 Jul 2025filed 31 Jul 2025 | Sage Therapeuticsoption or derivative | SEC FORM 4 Code D | —21,500 | filing |
| 31 Jul 2025filed 31 Jul 2025 | Sage Therapeutics | SEC FORM 4 Code U | —8,000 | filing |
| 14 Jul 2025filed 16 Jul 2025 | STTK Shattuck Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,150 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | Mural Oncologyoption or derivative | SEC FORM 4 Code A | —8,637 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | Sage Therapeuticsoption or derivative | SEC FORM 4 Code A | —21,500 at $0.00 | filing |
| 3 Jan 2025filed 6 Jan 2025 | Sage Therapeuticsoption or derivative | SEC FORM 4 Code A | —13,593 at $0.00 | filing |
| 30 Jul 2024filed 31 Jul 2024 | Mural Oncologyoption or derivative | SEC FORM 4 Code A | —15,334 at $0.00 | filing |
| 21 Jun 2024filed 21 Jun 2024 | STTK Shattuck Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,700 at $0.00 | filing |
| 10 Jun 2024filed 11 Jun 2024 | Sage Therapeuticsoption or derivative | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 3 Jan 2024filed 4 Jan 2024 | Sage Therapeuticsoption or derivative | SEC FORM 4 Code A | —3,495 at $0.00 | filing |
News
Comparing Amphastar Pharmaceuticals (NASDAQ:AMPH) & Enanta Pharmaceuticals (NASDAQ:ENTA)ENTA · tickerreport.com · 13 Oct 2026Contrasting Enanta Pharmaceuticals (NASDAQ:ENTA) and Scilex (NASDAQ:SCLX)ENTA · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name George Golumbeski; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.